ThermoGenesis, a wholly owned subsidiary of Cesca Therapeutics, is a pioneer and market leader in the development and commercialization of automated technologies for cell-based therapeutics and bio-processing. Cesca is a leading regenerative medicine company that develops, commercializes and markets a range of automated technologies for cell-based therapeutics. The Company’s device division, ThermoGenesis Corp., provides a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology. Cesca’s clinical development division is leveraging its proprietary AutoXpress® technology platform to develop autologous stem cell-based therapies that address significant unmet needs in the immuno-oncology, vascular, cardiology and orthopedic markets. Cesca is an affiliate of the BoyaLife Group, a China-based industry research alliance encompassing top research institutions for stem cell and regenerative medicine. Our mission is to be a leading provider of cellular bioprocessing technologies and autologous cell-based therapies for the regenerative medicine market. Our vision is to bring to bear the full potential of our proprietary, automated technologies for use in regenerative medicine. Through our device division, we aim to expand our footprint as a leading developer of innovative, automated cell processing technologies. Through our clinical development division, we will leverage our technology to develop cell-based therapies that address significant unmet medical needs in vascular diseases, cardiology, orthopedics, and immuno-oncology.
2711 Citrus Road
Rancho Cordova, California 95742